Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.
Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.
Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.
Savolitinib plus osimertinib was safe and effective in patients with EGFR-mutated, MET-amplified advanced NSCLC after disease progression on an EGFR TKI.
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.
Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.
The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.
Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.
